Saatci, Ozge http://orcid.org/0000-0002-0124-044X
Akbulut, Ozge http://orcid.org/0000-0002-3647-1969
Cetin, Metin
Sikirzhytski, Vitali
Uner, Meral
Lengerli, Deniz
O’Quinn, Elizabeth C.
Romeo, Martin J.
Caliskan, Burcu
Banoglu, Erden
Aksoy, Sercan
Uner, Aysegul
Sahin, Ozgur http://orcid.org/0000-0002-8033-7089
Funding for this research was provided by:
Susan G. Komen (GTDR17500160)
U.S. Department of Health & Human Services | National Institutes of Health (R01-CA251374, R01-CA267101, P30-CA138313)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
SmartState Endowment in Lipidomics and Drug Discovery
Article History
Received: 19 July 2022
Revised: 15 February 2023
Accepted: 20 February 2023
First Online: 2 March 2023
Competing interests
: OS, BC, and EB are the co-founders of OncoCube Therapeutics LLC, developing TACC3 inhibitors. OS is the founder and president of LoxiGen, Inc, developing lysyl oxidase inhibitors. The other authors declare no potential conflict of interest.
: The study was approved by the Non‐Interventional Clinical Research Ethics Committee of Hacettepe University (approval no: 2020/02-40). Informed consent was obtained from all patients.